Allergan’s $560M buyout deal just led to a PhIII debacle as another depression drug goes down to bitter defeat
Allergan’s $560 million deal to buy Naurex has led it straight down a blind alley for depression drugs, where it’s been mugged by a decisive set of failed late-stage data.
Brent Saunders’ biotech $AGN announced after the market closed that rapastinel had flunked the big set of Phase III studies used to test the drug for major depression. Topline results from 3 Phase III trials along with a late-stage test on relapses proved conclusively that the drug had none of its intended effects — either on the primary or secondary endpoints.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
